The Generation and Preclinical Evaluation of Homodimeric Anti-Her-2 Antibodies
Abstract
Her-2/neu has been selected as a target for immunotherapy based on its prevalence on a variety of tumor cells and the poor prognosis associated with its overexpression. From a panel of a hundred a-Her-2 MAbs we have characterized eleven with the highest affinity for Her-2 for further study in the treatment of prostate cancer. Three were eventually chosen for testing as homodimers and all induced substantially more growth arrest and death in vitro than their corresponding monomers. Work has also begun converting a number of these MAbs into mouse/human chimeric IgG1/k into which we have incorporated cysteine residues for homodimer formation. These genetic dimers will be evaluated for efficacy in our in vitro models.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2002
- Accession Number
- ADA410714
Entities
People
- Ellen S. Vitetta
Organizations
- University of Texas Southwestern Medical Center